Rheumatology International

, Volume 28, Issue 6, pp 561–566 | Cite as

Automated neuropsychiatric measurements of information processing in fibromyalgia

  • Brian WalittEmail author
  • Tresa Roebuck-Spencer
  • Joseph Bleiberg
  • Gregory Foster
  • Arthur Weinstein
Original Article


Aberrant central neurological functioning is believed to contribute to the abnormal sensations of fibromyalgia (FM). Most patients with FM complain of diminished cognitive function. This study sought to compare objective cognitive function between FM and healthy controls at baseline and to determine if symptomatic improvement was related to objective cognitive improvement. Automated neuropsychological assessment metrics (ANAM) was used to quantify neurocognitive function. Performance on ANAM was compared between subjects with FM, musculoskeletal pain, and pain-free controls. Ten separate FM subjects completed an 8-week comprehensive treatment program. Serial testing with ANAM and the Fibromyalgia Impact Questionnaire was conducted. Statistical analysis was performed using repeated Wilcoxon signed rank tests. No differences were noted on ANAM between controls and subjects with pain disorders. A clinical improvement (FIQ median change 33.9, P = 0.002) was noted with treatment without concomitant change in ANAM scores. No cognitive impairment in FM was demonstrated using ANAM.


Fibromyalgia Neuropsychological tests ANAM 



The study group would like to acknowledge the efforts of Teresa Hunt, Cognitive Behavioral Therapist, Nancy Shaw, Physical Therapist, and Daniel Frisch, Neuroscience Research Associate for their efforts. This study would not have been possible without the grant support from the MedStar Research Institute and Pfizer Pharmaceuticals.


  1. 1.
    Katz R, Heard A, Mills M, Leavitt F (2004) The prevalence and clinical impact of reported cognitive difficulties (fibrofog) in patients with rheumatic disease with and without fibromyalgia. J Clin Rheumatol 10(2):53–58PubMedCrossRefGoogle Scholar
  2. 2.
    Glass JM, Park DC (2001) Cognitive dysfunction in fibromyalgia. Curr Rheumatol Rep 3(2):123–127PubMedCrossRefGoogle Scholar
  3. 3.
    Grace GM, Nielson WR, Hopkins M, Berg MA (1999) Concentration and memory deficits in patients with fibromyalgia syndrome. J Clin Exp Neuropsychol 21(4):477–487PubMedCrossRefGoogle Scholar
  4. 4.
    Landro NI, Stiles TC, Sletvold H (1997) Memory functioning in patients with primary fibromyalgia and major depression and healthy controls. J Psychosom Res 42(3):297–306PubMedCrossRefGoogle Scholar
  5. 5.
    Park DC, Glass JM, Minear M, Crofford LJ (2001) Cognitive function in fibromyalgia patients. Arthritis Rheum 44(9):2125–2133PubMedCrossRefGoogle Scholar
  6. 6.
    Dick B, Eccleston C, Crombez G (2002) Attentional functioning in fibromyalgia, rheumatoid arthritis, and musculoskeletal pain patients. Arthritis Rheum 47(6):639–644PubMedCrossRefGoogle Scholar
  7. 7.
    Suhr J (2003) Neuropsychological impairment in fibromyalgia: relation to depression, fatigue, and pain. J Psychosom Res 55:321–329PubMedCrossRefGoogle Scholar
  8. 8.
    Bleiberg J, Kane R, Reeves D et al (2000) Factor analysis of computerized and traditional tests used in mild brain injury research. Clin Neuropsychol 14(3):287–294PubMedGoogle Scholar
  9. 9.
    Kay G, Berman B, Mockoviak S, Morris C, Reeves D et al (1997) Initial and steady-state effects of diphenhydramine and loratadine on sedation, cognition, mood, and psychomotor performance. Arch Intern Med 157(20):2350–2356PubMedCrossRefGoogle Scholar
  10. 10.
    Farmer K, Cady R, Bleiberg J, Reeves D (2001) An open label study to evaluate the effects of sumatriptan nasal spray (20 mg) on cognitive efficiency during migraine. Headache 41(4):377–384PubMedCrossRefGoogle Scholar
  11. 11.
    Bleiberg J, Cernich AN, Cameron K, Sun W, Peck K, Ecklund LP, et al (2004) Duration of cognitive impairment after sports concussion. Neurosurgery 54(5):1073–1080PubMedCrossRefGoogle Scholar
  12. 12.
    Farmer K, Cady R, Bleiberg J, Reeves D (2000) A pilot study to measure cognitive efficiency during migraine. Headache (40)8:657–661PubMedCrossRefGoogle Scholar
  13. 13.
    Roebuck-Spencer TM, Yarboro C, Lapteva L, Frisch D, Nowak M, Weickert TW, Ilei G, Bleiberg J (2004) The contribution of cognitive versus non-cognitive factors to ANAM performance in a Lupus population. Arch Clin Neuropsychol 19(7):947–948 (Abstract)Google Scholar
  14. 14.
    Wolfe F, Smythe HA, Yunus M et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. Arthritis Rheum 33:160–172PubMedCrossRefGoogle Scholar
  15. 15.
    Spreen O, Strauss E (1998) A compendium of neuropsychological tests: administration, norms, and commentary, 2nd edn. Oxford University Press, New YorkGoogle Scholar
  16. 16.
    Golden CJ (1978) Stroop color and word test. Western Psychological Services, Los AngelesGoogle Scholar
  17. 17.
    Radloff LS (1997) The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1:385–401CrossRefGoogle Scholar
  18. 18.
    Callahan LF, Kaplan MR, Pincus T (1991) The beck depression inventory, center for epidemiological studies depression scale (CES-D), and general well-being schedule depression subscale in rheumatoid arthritis. Arthritis Care Res 4(1):3–11PubMedCrossRefGoogle Scholar
  19. 19.
    Ercolani M, Trombini G, Chattat R, Cervini C, Piergiacomi G, Salaffi F, Zeni S, Marcolongo R (1994) Fibromylagic syndrome: depression and abnormal illness behavior. Multicenter investigation. Psychother Psychosom 61(3–4):178–186PubMedCrossRefGoogle Scholar
  20. 20.
    Wilkinson GS (1993) Wide range achievement test (WRAT-3). Psychological Corporation, WilmingtonGoogle Scholar
  21. 21.
    Burckhardt C, Clark S, Bennett R (1991) The fibromyalgia impact questionnaire: development and validation. J Rheumatol 18:728–733PubMedGoogle Scholar
  22. 22.
    Fallon J, Bujak D, Guardino S, Weinstein A (1999) The fibromyalgia impact questionnaire: a useful tool in evaluating patients with post-lyme disease syndrome. Arthritis Care Res 12(1):42–47PubMedCrossRefGoogle Scholar
  23. 23.
    Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C (1996) A randomized double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 39:1852–1859PubMedCrossRefGoogle Scholar
  24. 24.
    Box GEP, Cox DR (1964) An analysis of transformations. J R Stat Soc B26:211–243Google Scholar
  25. 25.
    Bleiberg J, Cernich AN, Cameron KL, Sun W, Peck K, Uhorchak K, Reeves DL, Ecklund J, Sparling MB, Warden D (2004) Duration of cognitive impairment following sports concussion. Neurosurgery 54(4):1–6Google Scholar
  26. 26.
    Bleiberg J, Garmoe WS, Halpern EL, Reeves DL, Nadler JD (1997) Consistency of within-day and across-day performance after mild brain injury. Neuropsychiatry Neuropsychol Behav Neurol 10(4):247–253PubMedGoogle Scholar
  27. 27.
    Farmer K, Cady RK, Reeves D, Bleiberg J (2003) Cognitive efficiency following migraine therapy. In: Olesen J, Steiner TJ, Lipton RB (eds) Reducing the burden of headache: frontiers in headache research. Oxford University Press, New YorkGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Brian Walitt
    • 1
    Email author
  • Tresa Roebuck-Spencer
    • 2
  • Joseph Bleiberg
    • 2
  • Gregory Foster
    • 3
  • Arthur Weinstein
    • 1
  1. 1.Washington Hospital CenterWashingtonUSA
  2. 2.National Rehabilitation HospitalWashingtonUSA
  3. 3.MedStar Research InstituteHyattsvilleUSA

Personalised recommendations